COSMOS Pharmaceutical Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2023.  For the period, the company expects net sales of JPY 813,500 million, operating profit of JPY 30,000 million, profit attributable to owners of parent JPY 23,200 million and basic earnings per share of JPY 585.87.